110 related articles for article (PubMed ID: 31469900)
1. What Are Treatment Options After Progression in PDL-1-Positive Metastatic Lung Adenocarcinoma after Chemo/IO?
Remolina-Bonilla YA; Trejo-Rosales RR; Saldivar-Oviedo B; Gabutti A; Bourlon MT
Oncology (Williston Park); 2019 Aug; 33(8):. PubMed ID: 31469900
[No Abstract] [Full Text] [Related]
2. Combined Atezolizumab and Chemotherapy for a Patient With Double Primary Cancers.
Okauchi S; Sasatani Y; Ohara G; Kagohashi K; Satoh H
In Vivo; 2020; 34(1):389-392. PubMed ID: 31882503
[TBL] [Abstract][Full Text] [Related]
3. The Unforeseen Path to the Superior Vena Cava.
Boutros J; Benzaquen J; Marquette CH; Leroy S
Am J Respir Crit Care Med; 2021 Aug; 204(3):e51-e53. PubMed ID: 34166167
[No Abstract] [Full Text] [Related]
4. Prognostic value of cancer antigen -125 for lung adenocarcinoma patients with brain metastasis: A random survival forest prognostic model.
Wang H; Shen L; Geng J; Wu Y; Xiao H; Zhang F; Si H
Sci Rep; 2018 Apr; 8(1):5670. PubMed ID: 29618796
[TBL] [Abstract][Full Text] [Related]
5. BRIDGE: an open-label phase II trial evaluating the safety of bevacizumab + carboplatin/paclitaxel as first-line treatment for patients with advanced, previously untreated, squamous non-small cell lung cancer.
Hainsworth JD; Fang L; Huang JE; Karlin D; Russell K; Faoro L; Azzoli C
J Thorac Oncol; 2011 Jan; 6(1):109-14. PubMed ID: 21107290
[TBL] [Abstract][Full Text] [Related]
6. Randomized, double-blinded, multicenter, phase II study of pemetrexed, carboplatin, and bevacizumab with enzastaurin or placebo in chemonaïve patients with stage IIIB/IV non-small cell lung cancer: Hoosier Oncology Group LUN06-116.
Casey EM; Harb W; Bradford D; Bufill J; Nattam S; Patel J; Fisher W; Latz JE; Li X; Wu J; Hanna N
J Thorac Oncol; 2010 Nov; 5(11):1815-20. PubMed ID: 20881647
[TBL] [Abstract][Full Text] [Related]
7. [Combination therapy herceptin+xeloda].
Schaller G
Onkologie; 2002 Dec; 25 Suppl 5():17-8; discussion 19. PubMed ID: 23573615
[No Abstract] [Full Text] [Related]
8. Metastatic apocrine carcinoma of the scalp: prolonged response to systemic chemotherapy.
Tlemcani K; Levine D; Smith RV; Brandwein-Gensler M; Staffenberg DA; Garg MK; Shifteh K; Haigentz M
J Clin Oncol; 2010 Aug; 28(24):e412-4. PubMed ID: 20406935
[No Abstract] [Full Text] [Related]
9. Positive Conversion of PD-L1 Expression After Treatments with Chemotherapy and Nivolumab.
Haratake N; Toyokawa G; Tagawa T; Kozuma Y; Matsubara T; Takamori S; Akamine T; Yamada Y; Oda Y; Maehara Y
Anticancer Res; 2017 Oct; 37(10):5713-5717. PubMed ID: 28982891
[TBL] [Abstract][Full Text] [Related]
10. Response of metastatic renal medullary carcinoma to carboplatinum and Paclitaxel chemotherapy.
Gangireddy Vg; Liles GB; Sostre GD; Coleman T
Clin Genitourin Cancer; 2012 Jun; 10(2):134-9. PubMed ID: 22409864
[No Abstract] [Full Text] [Related]
11. Hypoxia-inducible factor-1α and excision repair cross-complementing 1 in patients with small cell lung cancer who received front-line platinum-based chemotherapy: a retrospective study.
Lee GW; Go SI; Cho YJ; Jeong YY; Kim HC; Duk Lee J; Hwang YS; Ko GH; Lee JH; Kim DC; Yang JW; Oh S; Lee JS
J Thorac Oncol; 2012 Mar; 7(3):528-34. PubMed ID: 22258474
[TBL] [Abstract][Full Text] [Related]
12. Switch maintenance therapy with S-1 after induction therapy with carboplatin and nanoparticle albumin-bound paclitaxel in advanced lung squamous cell carcinoma.
Akiyama N; Karayama M; Inui N; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Inami N; Matsuura S; Kaida Y; Uto T; Matsui T; Asada K; Matsuda H; Fujii M; Toyoshima M; Suda T
Invest New Drugs; 2019 Jun; 37(3):531-537. PubMed ID: 30790149
[TBL] [Abstract][Full Text] [Related]
13. Activity of pemetrexed-based regimen as first-line chemotherapy for advanced non-small cell lung cancer with asymptomatic inoperable brain metastasis: a retrospective study.
Zhu W; Røe OD; Wu C; Li W; Guo R; Gu Y; Liu Y; Shu Y; Chen X
J Chemother; 2015 Aug; 27(4):221-6. PubMed ID: 25735792
[TBL] [Abstract][Full Text] [Related]
14. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.
Reck M; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Vandormael K; Riccio A; Yang J; Pietanza MC; Brahmer JR
J Clin Oncol; 2019 Mar; 37(7):537-546. PubMed ID: 30620668
[TBL] [Abstract][Full Text] [Related]
15. Novel anticancers and dermatological adversities: old rivals but new challenges.
Sahu KK; Mishra A; Chastain I
BMJ Case Rep; 2018 Dec; 11(1):. PubMed ID: 30567273
[No Abstract] [Full Text] [Related]
16. Tumor lysis syndrome and acquired ichthyosis occurring after chemotherapy for lung adenocarcinoma.
Honda K; Saraya T; Tamura M; Yokoyama T; Fujiwara M; Goto H
J Clin Oncol; 2011 Dec; 29(35):e859-60. PubMed ID: 22042943
[No Abstract] [Full Text] [Related]
17. Complete and Sustained Response of Brain Metastases to Programmed Death 1 Antibody Monotherapy in Treatment-naive Programmed Death Ligand 1-Positive Lung Cancer.
Varkaris A; Sehgal K; Rangachari D; Costa DB
J Thorac Oncol; 2019 Feb; 14(2):e34-e36. PubMed ID: 30683297
[No Abstract] [Full Text] [Related]
18. Immunotherapy in Lung Cancer.
Du L; Herbst RS; Morgensztern D
Hematol Oncol Clin North Am; 2017 Feb; 31(1):131-141. PubMed ID: 27912829
[TBL] [Abstract][Full Text] [Related]
19. Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus.
Isla D; de Castro J; García-Campelo R; Lianes P; Felip E; Garrido P; Paz-Ares L; Trigo JM
Clin Transl Oncol; 2020 May; 22(5):759-771. PubMed ID: 31368078
[TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer.
Reck M
Immunotherapy; 2018 Feb; 10(2):93-105. PubMed ID: 29145737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
